We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adjuvant Derived From Marine Sponges Boosts Effect of COVID-19 Vaccine
News

Adjuvant Derived From Marine Sponges Boosts Effect of COVID-19 Vaccine

Adjuvant Derived From Marine Sponges Boosts Effect of COVID-19 Vaccine
News

Adjuvant Derived From Marine Sponges Boosts Effect of COVID-19 Vaccine

Credit: QUI NGUYEN on Unsplash.
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adjuvant Derived From Marine Sponges Boosts Effect of COVID-19 Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ironically, some vaccines need their own “boosters.” Adding an ingredient called an adjuvant can help vaccines elicit a more robust immune response, better training the body to fight a pathogen. In a new study in ACS Infectious Diseases, researchers report a substance that boosted the immune response to an experimental COVID-19 shot in mice by 25 times, compared to injection with the vaccine alone.

Although the first COVID-19 shots authorized in the U.S. apply cutting-edge genetic technology, the tried-and-true strategy of using proteins from the pathogen can produce vaccines that are less expensive to make and easier to store. So far, the U.S. Food and Drug Administration has authorized only one protein-based vaccine, made by Novavax, against SARS-CoV-2. However, many currently available inoculations against other diseases rely on proteins or pieces of them, and these shots contain adjuvants to enhance their effect. Researchers have found that molecules derived from α-galactosylceramide (αGC), a compound from marine sponges, can act as adjuvants by stimulating a small population of immune cells important for defending the body against viral infections. Rui Luo, Zheng Liu and their colleagues wanted to see if they could devise a version of αGC to significantly boost the immune response elicited by a protein-based COVID-19 vaccine.


The team made four analogs of αGC and added each to an experimental vaccine containing a piece of SARS-CoV-2’s spike protein, which the virus uses to infect cells. The researchers gave mice three injections over 29 days and tracked their immune response out to 35 days. To measure the effects of the adjuvants, they looked at various aspects of immune function, including two ways the immune system eliminates pathogens: through antibodies, which are immune proteins that latch onto an invader, and T cells, which kill diseased cells. None of the four meaningfully enhanced the T cell response, but all of them produced antibodies with a much greater capacity for interfering with the virus. The analog called αGC-CPOEt led to the production of antibodies with the greatest neutralizing capacity — 25 times greater than what the vaccine could elicit without an adjuvant. These results suggest αGC-CPOEt merits further investigation as a potential adjuvant to fight COVID-19 and other infectious diseases, the researchers say.


Reference: Li YQ, Yan C, Wang XF, et al. A new iNKT-cell agonist-adjuvanted SARS-CoV-2 subunit vaccine elicits robust neutralizing antibody responses. ACS Infect Dis. 2022. doi:10.1021/acsinfecdis.2c00296.


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement